Allander Biotechnologies is a start-up company aiming to develop proprietary biologics to improve wound healing and treat scar, fibrotic and inflammatory disorders.
Alpha Omega Alpha Honor Medical Society
Alpha Omega Alpha Honor Medical Society is a professional medical organization that recognizes and advocates for excellence in scholarship and the highest ideals in the profession of medicine. AΩA’s values include honesty, honorable conduct, morality, virtue, unselfishness, ethical ideals, dedication to serving others, and leadership. Members have a compelling drive to do well, advance the medical profession, and exemplify the highest standards of professionalism.
Alta Biotech, LLC
Alta Biotech, LLC is a Contract Research Organization (CRO) providing molecular biology, biochemistry, and cell biology services to fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Our mission is to deliver innovative and quality services that help customers advance scientific discovery and improve health.
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology.
Apspeeda Biosciences is a preclinical stage biopharmaceutical company focusing on anti-infective products for human use.
Artisan, is building a revolutionary platform for editing mammalian cells for therapeutic applications with commercial fidelity (accuracy, speed and low cost), repeatability and data transparency. Artisan’s platform both enables and accelerates the therapeutic revolution, currently best represented by several FDA-approved CAR-T therapies, in which a patient’s cells are altered to more effectively attack cancer. With CAR-T, a patient’s T Cells (a specific type of immune system cell) are extracted, edited (i.e., the cells are altered by adding the gene for a receptor – called a Chimeric Antigen Receptor, hence CAR-T -- that binds to a specific protein on the target cancer cells). Large numbers of the patient’s CAR-T cells are then grown in the lab and reinserted into the patient via infusion, where they directly attack tumors. CAR-T has demonstrated game-changing clinical effectiveness in treating very late stage cancer for which standard therapies have failed. More generally, CAR-T is the tip of an emerging new therapeutic modality, edited cell and gene therapies that enhance the body’s own immune system to attack disease, that will eventually become part of the standard therapeutic toolkit.
Aurora Oncology, Inc.
Aurora Oncology Inc. will commercialize products developed by its founders as part of their research endeavors at the University of Colorado Cancer Center. The lead product, EGF-DTA fusion protein, is intended to treat recurrent bladder cancer.
Avidity develops and sells molecular affinity tools for connecting molecules. Our patented AviTag™ technology employs a highly targeted enzymatic conjugation of a single biotin on a unique 15 amino acid peptide tag using the biotin ligase (BirA) from E. coli. Oriented on streptavidin-coated surfaces, this creates an ideal presentation for molecular binding interactions. Though Avidity is a small company, the scientific benefits of its AviTag have garnered notice. Currently, AviTag technology is licensed by seven of the world’s top ten pharmaceutical companies and is used by researchers in 22 countries.
The Department of Bioengineering offers high quality training in bioengineering that is flexible and multidisciplinary. A design-based focus permeates every aspect of our training philosophy which can be summarized by the following question: What does the user want and how can I utilize my bioengineering training to achieve this need?
BodySync is a wellness company that provides customized programs based on an individual’s personal genetics. The Company analyzes a discrete number of well-characterized genetic variations that have impact on nutrient metabolism and athletic performance. Each participant in a BodySync program takes a dietary and lifestyle survey to establish his/her own current dietary and wellness behavior. BodySync delivers proprietary Gene-LifeStyle™ integration of each participant’s genetic and lifestyle data to provide an Action Plan. The Action Plan identifies an individual’s current status and guides dietary intake and lifestyle changes in the direction of health and wellness predicated on each individual’s unique genetic profile. The Company partners with Health and Wellness Solutions providers that can leverage and tailor their products to benefit each unique individual.
Bond Pets is a pet food company, founded in their love for animals. They love animals, but what they don’t love is how the foundation of any good pet food — animal proteins — are sourced and made. They believe that one animal doesn’t need to be harmed to feed another. They don’t think antibiotics and pharmaceuticals need to be routinely given to most farm animals raised for meat. Or that the ever-present risk of foodborne illness from conventional meat processing is one our pets, or their parents, should have to take. They know the reality of pet food manufacturing today. They know it’s dirty. They know it’s held back by old systems of agriculture. And they know it strains our land, water and energy resources. But most of all they know they can do better.
Center for Surgical Innovation
The Center for Surgical Innovation (CSI) at the University of Colorado is a multidisciplinary surgical training center dedicated to promoting educational courses and development of leading edge surgical techniques and technologies. CSI was created as a local, national and international center of excellence in the evolving field of surgery. CSI is dedicated to teaching and disseminating leading edge surgical techniques to practicing surgeons, residents and medical students. Our comprehensive multi-specialty/multi-disciplinary group of faculty span all of the surgical specialties available at the University of Colorado Hospital.
Cerebral Therapeutics Inc. is a privately-held company founded with the goal of addressing the well recognized limitations of existing treatments for uncontrolled neurological diseases. With a promising route of administration, Cerebral Therapeutics offers a new approach to managing neurological diseases by means of delivering ideal dosing to targeted sites within the brain. Initially, Cerebral Therapeutics is focused on improving outcomes for patients with refractory epilepsy by targeting the site of the seizure generation and propagation in the brain. Future cerebral therapeutic areas include obesity, Alzheimer’s disease, Parkinson’s disease, anxiety spectrum disorder and brain cancer.
ClinImmune Labs comprises five laboratories: Histocompatibility, Clinical Immunology, Flow Cytometry, University of Colorado Cord Blood Bank, and Human Stem Cell Processing facility. These laboratories provide services to kidney, heart, lung, pancreas, and hematopoietic stem cell transplant programs around the world. They are located in offices and labs in the Bioscience 2 building.
Colorado Genetics Laboratory
Colorado Genetics Laboratory (CGL) is the premiere lab for cytogenetics and cytogenomics in the Rocky Mountain region. We are nationally recognized for excellence and provide state-of-the-art cytogenetic testing, as well as full interpretation of results and excellent customer service. Our Laboratory Directors and Genetic Counselors are available to discuss appropriate testing and test interpretation. Based in Aurora, CGL offers full service laboratory testing in prenatal, postnatal, cancer cytogenetics, fluorescence in situ hybridization (FISH), and chromosomal microarray (CMA).
Colorado Institute for Drug, Device & Diagnostic Development
Colorado Institute for Drug, Device & Diagnostic Development (CID4) provides management expertise to efficiently develop emerging life science technologies into commercial success. We do this by identifying and funding potential opportunities, and utilizing our advanced leadership team to ensure ultimate market value. Speed to market. Long-term gains. CID4 goes for high-impact results, getting big returns from big ideas.
Colorado Molecular Correlates Laboratory
The Colorado Molecular Correlates Laboratory (CMOCO) is a state-of-the-art facility, located in Bioscience 2 on the Anschutz Medical Campus/Fitzsimons Innovation Campus. The CMOCO Laboratory is dedicated to the development and implementation of predictive, prognostic and diagnostic molecular biomarker testing that will permit selection of cancer treatments with targeted therapy allowing for the best in personalized medicine.
Colorado Research Partners
Colorado Research Partners LLC is a new biotech company with a mission to develop treatments for sugar-based metabolic disorders. Recent studies suggest that fructose, present in added sugars such as high fructose corn syrup and table sugar, is have a major role in driving the epidemics of obesity and diabetes. Fructose produced endogenously is also playing a central role in a variety of kidney diseases. Our mission is to develop inhibitors that can block fructose metabolism or related enzymes that may be of use in the treatment of kidney disease and metabolic disorders.
CU Dermatopathology Consultants
The CU Dermatopathology Consultants perform a variety of dermatopathology services including evaluation of wet tissue, electron microscopy, consultative opinions, and direct/indirect immunofluorescence. We offer advanced immunohistochemical analysis of skin biopsies, with 143 available immunohistochemical stains and in-situ hybridization for selected disorders. We also offer limited ELISA assays to compliment our services. Our facility is certified by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA). www.cudermpath.com
The DARTNet Institute (DI) is a not-for-profit 501c3 corporation that was created to support collaboration between Practice-based Research Networks, academic health centers, clinicians, patients and other interested parties in the use of existing electronic data and the expansion of patient or staff reported data for research, quality improvement and safety.
Eleven P15, Inc.
Eleven P15 focuses on the development of biomarkers that enable early detection of idiopathic pulmonary fibrosis, and the discovery of genetically-targeted therapeutic approaches to treat and prevent this incurable disease.
Founded by doctors and scientists who understand the healing properties of CBD, Endourage manufactures and provides only the highest quality CBD oils and creams for those who need it most. They are healing the world with the creation of research-driven medical cannabinoid formulations. They achieve this by offering natural healing perfected through scientific research and testing. We are instilling confidence and trust in cannabinoid medicine. Endourage is committed to providing the highest quality, research-driven cannabinoid medicines to patients in need. They are visionaries and innovators who believe in the potential of CBD therapy, and are making the significant investment of resources required to produce Complete Spectrum™ formulations. Through continued research and development, they aim to drive awareness and adoption of quality CBD treatments that clinicians feel comfortable recommending to their patients.
Exxel Pharma is a biopharmaceutical company with a drug pipeline focused on non-addictive treatment of pain, PTSD and opiate addiction. The Company’s two lead therapeutics were acquired from the University of California, Irvine (UCI), and development activities are supported by grant and investor funding.
FindCure.org is a 501(c)(3) non-profit organization. It investigates and facilitates the availability of immune system modulating therapies for patients with chronic conditions such as allergies, asthma, cancer, chronic fatigue syndrome, colds, fibromyalgia, flu, hay fever, hepatitis, infections, Lyme disease, lymphoma and others. FindCure.org focuses on immunotherapeutic compounds that fight disease by enhancing the immune system rather than directly attacking the disease.
Gates Biomanufacturing Facility
The Gates Biomanufacturing Facility at the University of Colorado Anschutz Campus provides the following services for cell therapies and protein-based therapeutics: Process Development, Scale up, Manufacturing to cGMP standards, and Process documentation. We also focus on delivering Academic researchers, Clinicians, and Early stage biotechnology companies. Utilizing our expertise in Quality Assurance and Control and Process Development and Manufacturing, we help translate bench scale processes to optimized clinical-ready manufacturing processes and perform product manufacturing for early-phase clinical trials. By leveraging our existing current Good Manufacturing Practice (cGMP) facilities, trained staff, qualified equipment and best practices across each of our support services, investigators can significantly accelerate their timeline while minimizing their overall investment.
Greffex is the innovative global leader in the delivery of accelerated pandemic and bio-terror vaccines using the world’s first universal platform, our GREVAX™ Vaccine Platform. Our proven technology, the GREVAX™ Universal Platform, a fully-deleted, helper-independent adenoviral vector system, delivers unprecedented time-to-market, cost efficiency and safety. Our vibrant pipeline of vaccines, transplantation and gene therapy products continue to create value for our people, partners and investors.
iC42 – UCD Department of Anesthesiology
It is the goal of iC42 Clinical Research & Development to carry out pre-clinical and clinical drug development programs, to assist basic science departments to bring drug candidates into clinical development and to serve as a resource for biotech and pharmaceutical industry. One of the major foci is the evaluation of pharmacokinetics, drug metabolism and the development of clinical management tools for pediatric patients. Foremost iC42 Clinical Research & Development is a cutting-edge mass spectrometry laboratory with currently seventeen state-of-the-art LC-MS/MS systems. We are a unique facility since iC42 combines quantitative mass spectrometry (drugs, drug metabolites, other small molecules and large molecules, endogenous compounds), metabolic and protein profiling technologies under one roof. iC42 Clinical Research & Development is designed and uniquely qualified to carry out the bioanalytics for complex clinical trials involving drug quantification and molecular marker strategies.
IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen (HLA) genes. Our lead candidate drug is an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. Our goal is to preserve pancreatic beta cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes. We are leveraging our HLA platform to expand our pipeline beyond T1D, to include drug development for Celiac disease (gluten sensitivity) as well as potential additional autoimmune diseases.
Immunoah Therapeutics, Inc.
With the amazing success of CarT and anti PD-1 drugs in last few years, cancer immunotherapy has become the most exciting and powerful tools to defeat cancer in clinic. Immunoah Therapeutics, Inc. is a biotech startup company founded by Mile High Biomed, LLC at Denver, Colorado in October 2016. It focuses on researching and developing proprietary antibodies in the field of cancer immunotherapy. Since 2014, Mile High Biomed, LLC has developed a group of therapeutic mABs using its novel function screening platform. Based on these early discoveries, Immunoah Therapeutics, Inc. will begin to further validate the anti-cancer functions of those moleculars. We plan to move them to pre-clinical phases in 12-24 months. Min Wang, MD is the founder and CEO; Zhe Wang, PhD. MD serves as R&D director. The company currently has a startup fund of $200,000, and is actively seeking financial support from various sources including NIH SBIR and several international investors.
Impressio focuses on developing liquid-crystalline elastomers (LCEs) for use in load-bearing orthopedic applications such as knee and total disk replacement. Impressio is in the process of being incorporated into a Colorado C-class corporation. The technology of this company is being translated from University research from Professor Christopher Yakacki’s laboratory. Two provisional patents have been filed with CU Innovations. The company is ready to start prototyping and development.
Integrated Molecular Diagnostics Pathology, Inc.
Integrated Molecular Diagnostics Pathology, Inc. operates professional molecular laboratories specializing in advanced genomic testing. The Company solves problems presented by “standard” (non-targeted) cancer care which has historically relied on chemotherapy drugs and radiation therapy which can have adverse side effects, most specifically those of excessive toxicity and the increased risk of other forms of cancer. The Company provides pathologists and oncologists with advanced genomic testing as a means of targeting cancer care based on the detection and identification of abnormalities that may be found in cancerous tumors (otherwise referred to as the DNA Genomic Profile). Cancer treatments resultant from advanced genomic testing can be targeted, or customized, for individualized patient care providing reduced side effects from treatments and better outcomes in patient populations where such treatment is indicated.
Invenux, LLC is a privately held clinical stage biopharmaceutical company whose focus is the research and development of drugs for orphan diseases. Its first drug candidate is SCD-101 for the treatment of sickle cell disease. The primary goal of Invenux is to commercialize orphan drugs like SCD-101 through corporate partnerships that result in upfront, milestone and royalty payments or the outright sale of our rights to a pharmaceutical company.
InVitria, a division of Ventria Bioscience develops and sells blood-free and defined components and supplements for use in cell culture media, regenerative medicine, CAR-T, gene therapy, cell-based vaccines and tissue preservation. InVitria also offers custom media formulation services to help customers optimize performance, supply reliability, safety and consistency of their cell culture media.
Since 2002, Light Labs has successfully served the research marketplace with a wide array of laboratory goods out of their headquarters in Dallas, TX. In 2013, they set up operations in the Bioscience 1 building. Light Labs distributes PCR supplies, tissue culture supplies, pipette tips, microcentrifuge tubes, barrier tips, latex and nitrile gloves, centrifuge tubes, and much more. Stop by their store and see what they have to offer.
Living Ink Technologies
Living Ink transforms algae into the world’s most sustainable ink. This algae-derived ink will be leveraged to enter several market verticals that includes printing needs in industries such as packaging, marketing material, business cards, signs, and invitations/stationary, as well as the pen ink production industry.
Lohocla Research Corporation
Lohocla is a unique research and development company that analyzes the etiologic mechanisms of brain maladaptation which result in addiction to alcohol and other drugs, and produce chronic pain and major depressive disorder. Lohocla then uses “rational” drug design to generate small molecule pharmaceutics to normalize the maladapted neural systems. Lohocla has generated a molecular skeleton (platform) which it has used to create medications for reducing alcohol intake and craving in alcohol dependent individuals and has generated medications that can treat and prevent the development of several chronic pain syndromes. Lohocla’s strengths in discovery and proof of concept studies are supplemented by partnerships with entities who look for early stage entry into successful medication development efforts.
The goal of our company is to develop a new class of immunotherapies to unleash the power of the human body to fight against cancer or autoimmune diseases, such as psoriasis. Our approach takes advantage of a unique class of small molecules that can stimulate the human immune system to attack and destroy cancer cells or to prevent autoimmune malfunction.
MBC Pharma, Inc.
MBC Pharma, Inc. is a biopharmaceutical company focused on discovering and developing drugs for bone diseases such as cancer and osteoporosis. MBC Pharma’s comprehensive and patented technology enables the highly efficient and specific delivery of drugs to bone. The approach has yielded promising lead structures in preclinical development for the treatment of multiple myeloma, metastatic bone disease caused by breast, prostate and lung cancer as well as osteoporosis and osteopenia.
MenoGeniX is a clinical-stage biotechnology company developing MNGX-100, a therapeutic biologic, as a nonhormonal, non-SSRI/SNRI, alternative treatment for hot flashes and other vasomotor symptoms in women with natural or surgically-induced menopause as well as breast and prostate cancer patients undergoing hormone suppression or ablation. Data from a randomized, double-blind, placebo-controlled, phase Ib clinical trial in women with surgical and natural menopause, that was completed in 2014, are being used to design phase II/III clinical trials leading to registration. MenoGeniX’ goal is to find an industry partner, licensor or additional institutional investors.
Quantifying Stress. Meditation tools to create everyday mindfulness in your life.
MuscleSound provides immediate and actionable information to unlock the body’s full potential and improve overall muscle health.
We are developing a thermal stabilization platform technology for temperature sensitive vaccines and medicines with a patent pending photo-release formulation. We are using a safe, low cost, and scalable polymer that is well understood with a body of knowledge extending over 50 years. Nanoly Bioscience’s encapsulation and photo-release approach introduces minimal changes to administrative protocol for the vaccine or medicine. Our goal is to enable immunization access anywhere while simultaneously eliminating the refrigeration cost for lifesaving medicine.
The Neurometer® CPT® is a unique neurodiagnostic device that painlessly evalutes the functioning of small unmylenated (C), small myelinated (Aδ) and large myelinated (Aβ) sensory nerve fibers at any cutaneous site. It's sensitive to both hypoesthetic and hyperesthetic abnormalities and more than 800 peer reviewed research publications document its diagnostic capabilities. Since receiving FDA clearance in 1986, more than a million CPT® tests have been conducted around the world.
Omix Technologies, Inc is an S Corporation that functions solely as the owner of the two subsidiary LLCs Endura and Matriqs Biology. These two subsidiary LLCs were established to serve unique markets with different core competencies. The managing board includes Dr. Kirk Hansen, Dr. Angelo D’Alessandro, Mr. Travis Nemkov, and Mr. Ryan Hill all from the Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Denver.
Op-T has developed a diagnostic and therapeutic platform targeting autoimmune diseases.
Pathways Bioscience, Inc.
Pathways Bioscience, Inc. is an early stage bioscience company focused on discovering and developing new agents for modifying gene expression and regulating stress response pathways that contribute to cell defense mechanisms.
PhosphoSolutions, LLC was created to manufacture and distribute proprietary research tools, known as phospho-specific antibodies, which are at the cutting edge of proteomics. These antibodies are a key enabling technology used by biotech companies for both discovery and validation of new drugs. Founded by three of the world’s leading scientists in protein phosphorylation, the company’s unmatched expertise makes PhosphoSolutions the most qualified developer of custom-made phospho-specific antibodies. These antibodies greatly accelerate drug discovery and research in cancer and in neurological diseases such as Alzheimer’s.
Prolume has cloned and patented several genes from bioluminescent marine organisms that encode fluorescent and luminescent proteins. The company seeks to license these genes to companies for use in biomedicine and biotechnology – as components of platform technologies and as research or diagnostic reagents.
Our proprietary technology, enables Sepanta to be a service company that helps drug developing industries especially the ones that produce drugs with low solubility, absorption, and bioavailability (i.e. cancer drugs), not to overthink and overspend on the pharmacokinetics aspect of their drugs. Sepanta brings a safe, biocompatible, and biodegradable multi-cargo delivery platform that would complement future breakthroughs in medicine (i.e. delivery of gene-editor to the right location).
Shakabuku means to remove suffering and bring happiness to all people by awakening them to their inherent greatness. Shakabuku LLC was formed because of the growing opportunity to offer transformational State of Slim weight management services at a global level to millions of people seeking to lose weight, transform their lives and awaken to their full potential. Shakabuku LLC develops and manages the global expansion and distribution of State of Slim programs, products, and related services.
SHARKLET TECHNOLOGIES, LLC is a surface technology company that controls the growth of microorganisms through its revolutionary engineered topography, Sharklet™. Inspired by a shark skin pattern, Sharklet™ is the first, non-toxic, eco-friendly product ever created to truly inhibit or enhance the growth of microorganisms. There are two primary uses for Sharklet – marine and medical industries. In the medical device industry, the Sharklet™ pattern has already shown signs of radically increasing the amount of time it takes for bacterial biofilms to develop. Sharklet is now being tested with human protein conditions present to determine if bacterial biofilm formation can be inhibited for up to 21 days.
STAQ Pharma is a 503B outsourcing facility focused on sterile, pre-filled syringes of compounded medications.
Our goal is to develop a molecular test for HNC that is objective, highly sensitive, highly specific, easy-to-use, fast, low cost and non-invasive. We screened the human genome and identified a novel class of DNA-based biomarkers for human HNC. We developed a specific assay using a panel of these biomarkers, namely the “HNKlear” test. Data from the “HNKlear” test yield ~90% sensitivity and ~90% specificity in detecting HNC tissues and saliva. (Clinical Epigenetics 2018). The patent entitled “Biomarkers for head and neck cancer and methods of their use” (PCT/US2015/55958) is pending in both U.S. and China. A multi-center clinical trial, including the University of Colorado, Oregon Health and Science University, MD Anderson Cancer Center, Cornell University, China Medical University, and Dalian Medical University is underway. We are cleared to enroll the HNKlear test applications from medical institutions worldwide.
Taiga Biotechnologies, Inc.
Taiga Biotechnologies was founded to develop novel approaches to treat hematological diseases, including cancers, immunodeficiencies and autoimmune conditions. Our three-pronged approach combines novel breakthroughs in cellular, biologic and small molecule approaches to treat and manage these diseases. In August 2008, Taiga received its first small business innovation research grant from the Department of Health and Human Services, National Institute of Allergy and Infectious Disease. The grant will be used to further develop the proprietary technology to rapidly generate human therapeutic antibodies against influenza. In September 2008, Taiga received its second small business innovation research grant from the Department of Health and Human Services, National Heart, Lung, and Blood Institute. The grant will be used to further develop the proprietary technology for generating cell based therapies for the treatment of human disease.
TEQ Analytical Labs
TEQ Analytical Laboratories is the premier state of the art cannabis testing laboratory in the State of Colorado. Located at Bioscience 1 on the Anschutz Medical Campus, TEQ occupies a brand new, custom built 5,200 square foot laboratory.
Touch of Life Technologies
The human body is complex and beautiful. Artists through the ages have studied the human body in detail and healers have dissected and catalogued it. In 1993 scientists at the University of Colorado created the Visible Human by milling away millimeter slices of a cadaver and photographing the remaining block, thereby digitizing the anatomy. In this way they took the fascination we have for our own anatomy and brought it into the information age. Touch of Life Technologies (ToLTech) is the sole licensee of these innovations and is creating products that will allow students, practitioners and the public in general to better see, feel, and understand the beauty and complexity of the human body.
UBPBio manufactures and sells bioreagents related to the ubiquitin-proteasome pathway. The ubiquitinproteasome pathway is responsible for degradation of the majority of cellular proteins.
Ventria Bioscience, Inc.
Ventria Bioscience is a private biotechnology company developing therapeutic proteins targeting unmet medical needs in infectious disease and gastroenterology using ExpressTec. ExpressTec enables the large scale and cost-effective development and manufacturing of recombinant proteins.
Verkko Biomedical LLC
Verkko Biomedical, LLC was formed by Dr. Reed Ayers and Inga Tamayo. Reed Ayers is the inventor of the patented combustions synthesis technology for beta phase tricalcium phosphate manufacturing at Colorado School of Mines (CSM). Verkko Biomedical was formed to commercialize the combustion synthesis technology and manufacture medical grade customized alpha-, betaphase tricalcium phosphates (α-TCP, β-TCP) as precursor components for customers who operate in the biomedical/medical industry. Verkko will be operating in ceramic segment of the biomaterials market.
VisuGen Global, LLC
VisuGen Global will advance a new proprietary approach to concentrate and detect gene targets in a method that is simple to perform anywhere needed. The products will have high impact in that testing will be enabled in global regions and in on site locations where rapid results inform an actionable response. The technology is innovative and transformational and addresses unmet testing demands and broad-based market opportunities.
Vitan-Biotech LLC is an innovative company focusing on the developing nanobiotechnology for use in scientific research tools, biosensors, biochips/microarrays, nanopore sequencing, disease diagnostics and nucleic acid delivery. The company is currently engaged in developing novel Raman biotag for ultrasensitive infectious disease biomarker detection, in Slide-Based ELISA, IFA/IHC Immunoassays for Quantitation of low abundance but high value cancer biomarkers in clinical specimen, as well as in developing operation-free diagnostic kit for Far-forward Fieldable Applications. Vitan-Biotech’s nanobiotechnology will generate highly sensitive and economical assay platforms and diagnostic tools for clinical diagnosis and personalized care of the patient.
Western States Pathology
Western States Regional Oral & Maxillofacial Pathology Laboratory has been in continuous operation since 1978. It is the largest free-standing oral & maxillofacial pathology laboratory west of the Mississippi and has a regional referral base that includes ten states. The laboratory offers a large variety of pathology services including evaluation of tissue samples, consultative opinions, direct immunofluorescence and molecular pathology. The lab also offers advanced histochemical analysis of biopsy specimens and can provide in situ hybridization studies for clients as necessary. The medical director is a board certified oral & maxillofacial pathologist and the laboratory is licensed by CLIA (Clinical Laboratory Improvement Amendments).
Zalgen Labs, LLC
Zalgen Labs is a biotechnology company specializing in the design and production of superior biological molecules critical for the development and commercialization of reliable, rapid, and affordable diagnostic platforms, immunotherapeutics, and novel vaccines targeting neglected and underrepresented human infectious diseases. The company makes use of its proprietary expression platforms, including its patented mammalian cell-based biomanufacturing system, CHOLCelect, to deliver next generation biologicals to world health and biodefense settings.
Z Biotech, LLC
Z Biotech, LLC is dedicated to the advance of life science research and product development through the development and commercialization of innovative microarray platforms and carbohydrate standards. The goal of Z Biotech is to establish advanced carbohydrate libraries and to take these new products to multiplex microarray assays and eventually development of clinical diagnostics.
3D Biopsy, LLC
3DBiopsy, Inc.— founded by noted expert Drs. Stone, Crawford and Lucia—has developed a turnkey Biopsy System that uses three-dimensional (3D) imaging to map the prostate gland and correctly identifies clinically significant cancers with a 97% accuracy. The 3DBiopsy System includes a patented Biopsy Needle, patented Biopsy Actuator device, patent-pending Integrated Pathology System and 3D Mapping Software. This 4-part advance in the diagnosis and treatment of prostate cancer will result in a paradigm shift in the management of this disease— and ultimately, other cancers. With our System, as much as 67% of those patients will be spared radical treatment, and instead, be candidates for surveillance (no active treatment) or focal therapy.